Carey Ng - 15 May 2024 Form 4 Insider Report for Immix Biopharma, Inc. (IMMX)

Role
Director
Signature
/s/ Ilya Rachman as Attorney-In-Fact for Carey Ng
Issuer symbol
IMMX
Transactions as of
15 May 2024
Net transactions value
$0
Form type
4
Filing time
20 May 2024, 17:25:38 UTC
Previous filing
15 Sep 2023
Next filing
21 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMMX Common Stock 10,000 15 May 2024 Direct
holding IMMX Common Stock 1,025,221 15 May 2024 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMMX Stock Option (Right to Buy) Award $0 +21,587 $0.000000 21,587 15 May 2024 Common Stock 21,587 $2.47 Direct F2
transaction IMMX Stock Option (Right to Buy) Award $0 +25,512 $0.000000 25,512 15 May 2024 Common Stock 25,512 $2.47 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Carey Ng is the Managing Director of Mesa Verde Venture Partners III, LP ("Mesa Verde") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Ng disclaims beneficial ownership of the securities held by Mesa Verde, except to the extent of his pecuniary interest therein.
F2 Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024.
F3 The Stock Option will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

Remarks:

See Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the Reporting Person on December 15, 2021.